Muscle Invasive Schistosomal Squamous Cell Carcinoma of the Urinary Bladder: Frequency and Prognostic Significance of p53, BCL-2, HER2/neu, and Proliferation (MIB-1)

Human Pathology

Volumn 35, Issue 2, 2004, Pages 184-189

  Badr, Khaled M ^b   Nolen, J D L ^b   Derose, Patricia B ^b   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

Apoptosis; HER2 neu (c erb B 2); Mutant p53; Prognostic markers; Proliferation; Schistosomiasis; Squamous cell carcinoma; Urinary bladder carcinoma

Indexed keywords

AVIDIN; BIOLOGICAL MARKER; BIOTIN; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMATOXYLIN; KI 67 ANTIGEN; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; BLADDER CARCINOMA; BLADDER MUSCLE; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MUTANT; PROGNOSIS; SCHISTOSOMAL SQUAMOUS CELL CARCINOMA; SCHISTOSOMIASIS;

EID: 1242274544     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.10.006     Document Type: Article

References (35)

1. Murphy WM, Beckwith JB, Farrow GM: Tumors of the Kidney, Bladder, and Related Urinary Structures, Third Series, Fascicle 11. Washington, DC, Armed Forces Institute of Pathology, 1994
2. Ghoneim MA, el-Mekresh MM, el-Baz MA, et al: Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol 158:393-399, 1997
3. Sharfi AR, el Sir S, Beleil O: Squamous cell carcinoma of the urinary bladder. Br J Urol 69:369-371, 1992
4. Rundle JS, Hart AJ, McGeorge A, et al: Squamous cell carcinoma of bladder: A review of 114 patients. Br J Urol 54:522-526, 1982
5. Tiguert R, Lessard A, So A, et al: Prognostic markers in muscle invasive bladder cancer. World J Urol 20:190-195, 2002
6. Kamel D, Soini Y, Nuorva K, et al: p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with pre-malignant lesions. Virchows Arch 424:349-355, 1994
7. Warren W, Biggs PJ, el-Baz M, et al: Mutations in the p53 gene in schistosomal bladder cancer: A study of 92 tumors from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumors. Carcinogenesis 16: 1181-1189, 1995
8. Chaudhary KS, Lu QL, Abel PD, et al: Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous carcinoma of urinary bladder. Br J Urol 79:78-84, 1997
9. Ramchurren N, Cooper K, Summerhayes IC: Molecular events underlying schistosomiasis-related bladder cancer. Int J Cancer 62:237-244, 1995
10. Wu TT, Lee YH, Huang JK: p53 mutation and bcl-2 expression in transitional cell carcinoma of the urinary bladder. Zhonghua Yi Xue Za Zhi (Taipei) 64:9-14, 2001
11. Tenti P, Zappatore R, Romagnoli S, et al: p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: Correlation with histological parameters. J Pathol 178:65-70, 1996
12. Jahnson S, Risberg B, Karlsson MG, et al: p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 28:135-142, 1995
13. Korkolopoulou P, Christodoulou P, Kapralos P, et al: The role of p53, MDM2 and c-erbB-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 193:767-775, 1997
14. Koyuncuoglu M, Kargi A, Cingoz S, et al: Investigation of p53, c-cerbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Lett 126:143-148, 1998
15. Lipponen PK: Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer. Pathobiology 61:178-182, 1993
16. Moch H, Sauter G, Moore D, et al: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A 423:329-334, 1993
17. Nakopoulou L, Vourlakou C, Zervas A, et al: The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. HUM PATHOL 29: 146-154, 1998
18. Li B, Kanamaru H, Noriki S, et al: Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 26:235-241, 1998
19. Poliseno L, Mariani L, Collecchi P, et al: Bcl-2-negative MCF7 cells overexpress p53: Implications for the cell cycle and sensitivity to cytotoxic drugs. Cancer Chemother Pharmacol 50:127-130, 2002
20. Chiarugi V, Ruggiero M: Role of three cancer "master genes" p53, bcl-2, and c-myc on the apoptotic process. Tumori 82:205-209, 1996
21. Gorgoulis VG, Barbatis C, Poulias I, et al: Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinoma of the urinary bladder: A study in Greek patients. Mod Pathol 8:758-764, 1995
22. Lipponen P: Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 29A:749-753, 1993
23. Mazerolles C, Rishmann P, Chopin D, et al: Usefulness of MIB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: Comparison with Ki-67 antibody. Histopathology 25:563-568, 1994
24. Goel A, Abou-Ellela A, DeRose PB, et al: The prognostic significance of proliferation in prostate cancer: Image cytometric quantitation of MIB-1. J Urol Pathol 4:213-225, 1996
25. Chowdhury GM, Kojima K, Kanayama H, et al: The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer 78:827-833, 1996
26. Pfister C, Buzelin F, Casse C, et al: Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression. Eur Urol 33:278-284, 1998
27. Fleming ID, Cooper JS, Henson DE, et al (eds): American Joint Committee on Cancer Staging Manual, ed 5. Philadelphia, PA, Lippincott, 1997
28. Lohmann CM, League AA, Clark WS, et al: Bcl-2: bax and bcl-2:bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: Correlation with prognosis. Cytometry (Comm Clin Cytometry) 42:61-66, 2000
29. Baddoura FK, Cohen C, Unger ER, et al: Image analysis for quantitation of estrogen receptor in formalin-fixed, paraffin embedded sections of breast carcinoma. Mod Pathol 4:91-95, 1991
30. Jung I, Messing E: Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7:325-334, 2002
31. Pycha A, Mian C, Posch B, et al: Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: An alternative to classic prognostic indicators? Urology 53:1005-1010, 1999
32. Plastiras D, Moutzouris G, Barbatis C, et al: Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours? Eur J Surg Oncol 25:61-65, 1999
33. Kirsh EJ, Baunoch DA, Stadler WM: Expression of bcl-2 and bcl-x in bladder cancer. J Urol 159:1348-1353, 1998
34. Lipponen PK, Aaltomaa S, Eskelinen M: Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 28:135-140, 1996
35. Moch H, Sauter G, Mihatsch MJ, et al: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. HUM PATHOL 25:1346-1351, 1994